0000899243-20-034998.txt : 20201223 0000899243-20-034998.hdr.sgml : 20201223 20201223165240 ACCESSION NUMBER: 0000899243-20-034998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201221 FILED AS OF DATE: 20201223 DATE AS OF CHANGE: 20201223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolfe Lindsey CENTRAL INDEX KEY: 0001650504 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 201413168 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-21 0 0001466301 Clovis Oncology, Inc. CLVS 0001650504 Rolfe Lindsey C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2020-12-21 4 M 0 3438 A 60003 D Common Stock 2020-12-21 4 S 0 1728 5.68 D 58275 D Restricted Stock Units 2020-12-21 4 M 0 3438 0.00 D Common Stock 3438 0 D Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance /s/ Lindsey Rolfe 2020-12-23